Psoriatic Arthritis News

• EULAR 2023 HIIT Has Sustainable Effects in Inflammatory Arthritis Patients in a randomized trial improved their cardiorespiratory fitness, but the positive response did not coincide with changes in pain or fatigue.
  Medscape Medical News, June 09, 2023
• EULAR 2023 EULAR PsA Update Emphasizes Safety, Non-MSK Manifestations The update builds on 2019 recommendations and incorporates safety concerns about JAK inhibitors, advises on differential drug efficacy across disease manifestations, and eliminates systemic steroids.
  Medscape Medical News, June 09, 2023
• Alert EU Approves Bimekizumab for PsA and AxSpA The drug is the first IL-17 inhibitor approved to treat both conditions.
  Medscape Medical News, June 08, 2023
• Why Not Both? Dual Biologics for RA and PsA Previous clinical trials of dual biologic therapies have raised safety issues, but more recent, promising findings from clinical trials and case series have renewed interest in the treatment approach.
  Medscape Medical News, June 02, 2023
• EULAR 2023 ILD Risk Elevated in RA, PsA After Starting DMARDs The risk for interstitial lung disease in patients with PsA during the first 5 years was five times higher than for the general population, and the risk was not modified by methotrexate use.
  MDedge News, June 01, 2023
• Alert First IL-17 Inhibitor Approved in Europe for HS Patients The European Commission has approved the first interleukin-17A inhibitor for treating hidradenitis suppurativa.
  Medscape Medical News, June 01, 2023
• Enthesitis Linked to Dupilumab Use for Atopic Dermatitis Musculoskeletal symptoms identified in some patients treated with dupilumab for atopic dermatitis could help further understanding of how enthesitis develops.
  Medscape Medical News, May 31, 2023
• Alert FDA Approves Yuflyma as Ninth Adalimumab Biosimilar The manufacturer, Celltrion, is also seeking an interchangeability designation from the FDA, which is tentatively expected in the fourth quarter of 2024.
  Medscape Medical News, May 24, 2023
• Alert FDA Approves Autoinjector Pen for Humira Biosimilar, Cyltezo The drug will be commercially available on July 1, 2023.
  Medscape Medical News, May 22, 2023
• SPARTAN 2023 TNF, JAK Inhibitors' CV Safety Compared in PsA, AxSpA JAK inhibitors were not associated with higher risk of myocardial infarction or stroke and venous thromboembolism, compared with TNF-inhibitor users, in a small study.
  MDedge News, May 19, 2023
• Alert FDA Approves Upadacitinib (Rinvoq) for Crohn's Disease The oral JAK inhibitor is for adults with moderately to severely active Crohn's disease whose condition failed to respond adequately or who can't tolerate one or more TNF inhibitors.
  Medscape Medical News, May 18, 2023
• Brepocitinib Shows Promise for Patients With PsA Data from a phase 2b trial showed superior symptom reduction, compared with placebo, by 1 year.
  MDedge News, May 17, 2023
• Axial SpA vs Axial PsA: Different Entities? Features of axial psoriatic arthritis and axial spondyloarthritis overlap, but whether they're different diseases or on the same spectrum is unclear.
  MDedge News, May 09, 2023
• BSR 2023 Meta-Analysis Probes Cancer Risk Concern for JAK Inhibitors Although no increased cancer risk was seen vs methotrexate or placebo, Janus kinase inhibitors were associated with a higher cancer risk than were tumor necrosis factor inhibitors in a meta-analysis.
  Medscape Medical News, April 26, 2023
• NPF Provides Guidance for Virtual Psoriasis Visits In some cases, telemedicine may allow dermatologists specializing in psoriasis care to extend their reach in comanaging patients with primary care physicians and community dermatologists.
  MDedge News, April 24, 2023
• Alert FDA Approves New Formulation of Hyrimoz Adalimumab Biosimilar The agency approved a higher concentration formulation of Hyrimoz for its previous indications, including rheumatoid arthritis and psoriasis.
  Medscape Medical News, March 27, 2023
• Managing Inflammatory Rheumatism With Diet and Nutrition Patients with inflammatory rheumatic diseases often change their diets. A rheumatologist recently reviewed the data about this approach to disease management.
  Medscape Medical News, March 24, 2023
• AAD 2023 Dermatology Risks Are Likely Different for JAK Inhibitors Black box warnings for JAK inhibitors arise from rheumatoid arthritis studies, leading one expert to question the risk-benefit relevance to dermatologic diseases, particularly in younger patients.
  Medscape Medical News, March 18, 2023
• Biologics May Delay Arthritis in Psoriasis Patients Treatment with the interleukin-12/23 inhibitor ustekinumab or interleukin-23 inhibitors was linked to a lower risk of developing psoriatic arthritis compared with tumor necrosis factor inhibitors.
  MDedge News, March 09, 2023
• Isolated Nail Psoriasis May Be Sign of Psoriatic Arthritis In the review of 87 cases, the authors documented clinical and histologic features in patients with isolated nail psoriasis.
  MDedge News, February 28, 2023